All‐cause mortality · Patients on long‐term anticoagulant therapy (treatment duration longer than two months) irrespective of the indication for treatment
self‐management of oral anticoagulation probably leads to lower all‐cause mortality compared with standard care (moderate certainty).
1 finding from 1 review
Major bleeding · Patients on long‐term anticoagulant therapy (treatment duration longer than two months) irrespective of the indication for treatment
self‐management of oral anticoagulation showed no clear difference in major haemorrhage compared with standard care (low certainty).
1 finding from 1 review
Minor haemorrhage · Patients on long‐term anticoagulant therapy (treatment duration longer than two months) irrespective of the indication for treatment
self‐management of oral anticoagulation showed no clear difference in minor haemorrhage compared with standard care (low certainty).
1 finding from 1 review
Thromboembolic events · Patients on long‐term anticoagulant therapy (treatment duration longer than two months) irrespective of the indication for treatment
Self‐monitoring of oral anticoagulation probably leads to lower thromboembolic events compared with standard care (moderate certainty).
1 finding from 1 review
All‐cause mortality · Patients on long‐term anticoagulant therapy (treatment duration longer than two months) irrespective of the indication for treatment
Self‐monitoring of oral anticoagulation showed no clear difference in all‐cause mortality compared with standard care (moderate certainty).
1 finding from 1 review
Major bleeding · Patients on long‐term anticoagulant therapy (treatment duration longer than two months) irrespective of the indication for treatment
Self‐monitoring of oral anticoagulation showed no clear difference in major haemorrhage compared with standard care (low certainty).
1 finding from 1 review
Minor haemorrhage · Patients on long‐term anticoagulant therapy (treatment duration longer than two months) irrespective of the indication for treatment
Self‐monitoring of oral anticoagulation showed no clear difference in minor haemorrhage compared with standard care (moderate certainty).
1 finding from 1 review
Thromboembolic events · Patients on long‐term anticoagulant therapy (treatment duration longer than two months) irrespective of the indication for treatment
self‐management of oral anticoagulation probably leads to lower thromboembolic events compared with standard care (moderate certainty).
1 finding from 1 review
All‐cause mortality · children with or without anaemia at baseline
Oral iron with antimalarial prophylaxis showed no clear difference in all‐cause mortality compared with placebo or no treatment (low certainty).
1 finding from 1 review
RR 1.05 [0.52, 2.11]
728 participants
Low
Clinical malaria · children with or without anaemia at baseline
Oral iron with antimalarial prophylaxis leads to lower clinical malaria compared with placebo or no treatment (high certainty).
1 finding from 1 review
RR 0.54 [0.43, 0.67]
728 participants
High
Adverse events · Adults with cancer receiving treatment
1 finding from 1 review
Interruptions to cancer treatment (radiotherapy breaks longer than two days) · Adults with cancer receiving treatment
Epidermal growth factor (EGF), oral spray showed no clear difference in interruptions to cancer treatment (radiotherapy breaks longer than… compared with placebo; GRADE not reported.
1 finding from 1 review
Normalcy of diet (total parenteral nutrition) · Adults with cancer receiving treatment
Epidermal growth factor (EGF), oral spray showed no clear difference in normalcy of diet (total parenteral nutrition) compared with placebo; GRADE not reported.
1 finding from 1 review
Adverse events · Adults receiving chemotherapy alone for colorectal cancer
1 finding from 1 review
Apixaban (all doses combined) vs placebo · adults after AMI without an indication for anticoagulation
3 findings from 1 review
no estimate extracted
2 studies · 8638 participants
Moderate
no estimate extracted
2 studies · 8638 participants
Moderate
no estimate extracted
2 studies · 8544 participants
High
Rivaroxaban (all doses combined) vs placebo · adults after AMI without an indication for anticoagulation
3 findings from 1 review
no estimate extracted
3 studies · 21870 participants
High
no estimate extracted
3 studies · 21870 participants
Moderate
no estimate extracted
3 studies · 21870 participants
High
Dabigatran (all doses combined) vs placebo · adults after AMI without an indication for anticoagulation
3 findings from 1 review
no estimate extracted
1 study · 1861 participants
Low
no estimate extracted
1 study · 1861 participants
Low
no estimate extracted
1 study · 1861 participants
Low
Caries (DMFT) and enamel defects · Preterm children (about 8 years old) in the United Arab Emirates (Dubai)
One study found preterm children had higher DMFT and a fourfold higher prevalence of enamel defects than full-term children (narrative synthesis; not GRADE-rated).
1 finding from 1 review
Alshehhi et al. (Dubai) reported a significantly higher mean DMFT (1.00 vs 0.38) and a 4-times higher prevalence of enamel defects (58.15% vs 24.2%; OR 4.33, 95% CI 2.01-9.36) in preterm vs full-term children, highest…
1 study
GRADE not reported
All‐cause mortality · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
Direct oral anticoagulant (DOAC) prophylaxis showed no clear difference in mortality compared with no prophylaxis (moderate certainty).
1 finding from 1 review
Pulmonary embolism · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
Direct oral anticoagulant (DOAC) prophylaxis probably leads to lower pulmonary embolism compared with no prophylaxis (moderate certainty).
1 finding from 1 review